CETYLEV Drug Patent Profile

When do Cetylev patents expire, and when can generic versions of Cetylev launch?

Cetylev is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are three patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in CETYLEV is acetylcysteine. There are three drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the acetylcysteine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cetylev

A generic version of CETYLEV was approved as acetylcysteine by HOSPIRA on August 30^th, 1994.

Summary for CETYLEV

International Patents:	1
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	5,662
Drug Prices:	Drug price information for CETYLEV
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CETYLEV
DailyMed Link:	CETYLEV at DailyMed

See drug prices for CETYLEV

Recent Clinical Trials for CETYLEV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Maryland	Phase 1/Phase 2
University of Maryland, Baltimore	Phase 1/Phase 2

See all CETYLEV clinical trials

US Patents and Regulatory Information for CETYLEV

CETYLEV is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No	9,561,204
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No	8,747,894		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No	8,747,894		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No	9,427,421		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No	9,427,421		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No	9,561,204

International Patents for CETYLEV

See the table below for patents covering CETYLEV around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2662077	COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE)
European Patent Office	2662077	COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE)

CETYLEV Market Dynamics and Financial Trajectory: Uptake, Pricing, Competition, and IP/Gx Launch Risk

Last updated: July 30, 2026

CETYLEV’s market trajectory is not determinable from the available information in this session. No verified data is provided on: (1) FDA approval status and date, (2) labeled indication(s), (3) dosage form and NDC launch configuration, (4) manufacturer(s) and whether CETYLEV is a branded single product or a branded combination, (5) current pricing benchmarks, (6) net sales history by year/quarter, (7) payer coverage and formulary status, (8) contract terms or rebates, (9) presence of competing brands, authorized generics, biosimilars, or generics, or (10) relevant Orange Book listings, exclusivity, or Paragraph IV litigation that would drive near-term commercial ramp and share shifts.

Because CETYLEV’s financial and market dynamics depend on those hard inputs, a complete and accurate analysis cannot be produced under the constraints.

Key Takeaways

• CETYLEV’s market dynamics and financial trajectory cannot be quantified or validated without FDA status, commercialization entities, pricing/coverage, and sales data.
• Any attempt to infer figures or timelines would risk producing incorrect, non-actionable guidance for licensing, litigation, regulatory, or investment decisions.
• No patent/IP-driven launch risk assessment is possible for CETYLEV without Orange Book and litigation status.

1) What is CETYLEV’s current market position and who sells it?

No verified commercialization entity, indication, launch date, or performance metrics are available in this session. Without those facts, the product’s market position cannot be anchored to revenue share, penetration, or formulary access.

What indication drives CETYLEV demand?

Indication and patient pool characteristics are required to map demand drivers. No indication data is provided.

Which dosage forms and strengths matter commercially?

CETYLEV’s dosage form and strengths determine channel mix, dose utilization, and rebate structure. No product configuration is provided.

2) How fast does CETYLEV ramp and what is the revenue trajectory to date?

Revenue trajectory requires audited or company-reported net sales (or credible third-party estimates) over time. No net sales series is provided.

Quarterly and annual sales trajectory

No historical sales numbers exist in the provided information.

Channel mix: buy-and-bill vs specialty pharmacy

Channel classification is required to translate demand into cash flow patterns. No channel data is provided.

3) What is CETYLEV priced at and how do payers cover it?

Pricing and coverage are decisive for uptake curves. No list price, WAC, net price, rebate levels, or formulary tiering is provided.

List price vs net price drivers

Rebates and patient assistance materially change realized revenue. No contract terms are provided.

Formulary status and managed entry agreements

No evidence is provided for tier placement, prior authorization policies, step edits, or outcomes-based contracts.

4) What competitive landscape affects CETYLEV share?

A competitive analysis requires at least: (1) active ingredient(s), (2) therapeutic class, (3) clinically relevant comparators, (4) FDA-approved alternatives, and (5) pipeline threats. None of these are provided.

Brand competitors and same-class products

No competitor list is available.

Generic or biosimilar pressure

No evidence is provided for generic or biosimilar availability.

5) When could generics or biosimilars erode CETYLEV pricing and volume?

Generic/biosimilar risk depends on FDA exclusivity, patent life, and litigation. No Orange Book entries, patent expiration dates, or settlement records are provided.

Orange Book status for CETYLEV

No Orange Book status is available in this session.

Paragraph IV and settlement timelines

No Paragraph IV filings or settlements are provided.

6) What patents protect CETYLEV and how strong is the estate?

Patent strength and litigation outcomes depend on enumerated patent numbers, claims, filing/grant/expiration dates, and enforcement posture. No CETYLEV patent list is provided.

Composition, formulation, and method-of-use coverage

No patents are provided.

Patent litigation affecting CETYLEV

No litigation dockets or disputes are provided.

7) How does CETYLEV compare with alternative therapies on utilization and economics?

Comparative economic position requires acquisition cost per course, adherence, administration burden, and clinical pathway fit. No CETYLEV clinical or economic descriptors are provided.

Real-world utilization drivers

No utilization data is provided.

Health-economic endpoints used by payers

No outcomes or cost-effectiveness evidence is provided.

8) What is the investment or licensing outlook for CETYLEV partnerships?

Deal value depends on product performance, margin profile, and IP defensibility. No CETYLEV partnership/licensing history or financial terms are provided.

Technology licensing and co-promotion structures

No deal terms are provided.

Margin profile and manufacturing/IP barriers

No COGS, manufacturing model, or tech transfer constraints are provided.

---

Key Takeaways

• CETYLEV’s market and financial trajectory cannot be substantiated with the information available in this session.
• A decision-grade analysis requires validated commercialization facts (FDA status), revenue and pricing data, and IP/exclusivity artifacts.
• Without those, any quantified conclusions would be non-actionable.

FAQs

1. What is CETYLEV’s FDA approval date and what is its labeled indication?
2. Is CETYLEV listed in the FDA Orange Book, and when do its key patents expire?
3. Are there any pending Paragraph IV ANDA challenges against CETYLEV?
4. What is CETYLEV’s current pricing (WAC) and estimated net price after rebates?
5. Which products compete with CETYLEV in formulary placement and step therapy?

---

References (APA)

No sources were cited because CETYLEV-specific facts (FDA status, Orange Book listings, pricing, sales, or litigation) were not provided in this session.